Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Status:
Not yet recruiting
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
This phase I/II trial tests the safety and side effects of atezolizumab in combination with
cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has
come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help control the
disease in patients with recurrent glioblastoma.